These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36864802)

  • 1. MYELODYSPLASTIC SYNDROME: DIAGNOSIS, TREATMENT AND PROGNOSIS (LITERATURE REVIEW).
    Baidurin S; Akhmetzhanova S; Ilmalieva A; Sagyndykova G; Orazbekova A
    Georgian Med News; 2023 Jan; (334):103-107. PubMed ID: 36864802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
    Sekeres MA; Taylor J
    JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Identification of myelodysplastic syndromes patients].
    Santini V
    Recenti Prog Med; 2014 Mar; 105(3):127-31. PubMed ID: 24675456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
    Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
    Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and treatment of childhood myelodysplastic syndrome].
    Hasegawa D
    Rinsho Ketsueki; 2021; 62(4):229-238. PubMed ID: 33967145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
    Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
    Montalban-Bravo G; Garcia-Manero G
    Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
    Uchida T; Hagihara M; Hua J; Inoue M
    Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2011 Jun; 86(6):490-8. PubMed ID: 21594886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
    Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
    Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment for myelodysplastic syndromes and future perspectives in the genomic era].
    Maeda T
    Rinsho Ketsueki; 2021; 62(8):1038-1049. PubMed ID: 34497190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognosis and Therapy of Myelodysplastic Syndrome].
    Bonadies N
    Ther Umsch; 2022; 79(2):93-105. PubMed ID: 35291847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.